NEW YORK, March 1 /PRNewswire/ -- On February 27, Geert Kersten, CEO of CEL-SCI Corp. updated the investment community in an all-new, exclusive interview with www.wallst.net. Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.
To hear the interview in its entirety, visit www.wallst.net , and click on “Interviews/Podcasts”. Interviews require free registration, and can be accessed either by locating the respective company’s ticker symbol under the appropriate exchange on the left-hand column of the “Interviews/Podcasts” section of the site, or by entering the respective company’s ticker symbol in the Search Archive window.
About CEL-SCI Corp.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company’s lead product Multikine(R) is cleared to enter Phase III clinical trials with advanced primary head and neck cancer patients. Other products, in the pre-clinical stage and funded with U.S. government support, have induced protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.
About WallSt.net
www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community-driven applications for investors. www.wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. In addition to its website, WallStreet Direct organizes investor conferences, publishes a newspaper, and provides multimedia advertising solutions to small and mid-sized publicly traded companies. We are expecting to receive one hundred seventy five dollars from CEL-SCI Corp. for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp
Contact: Nick Iyer Digital Wall Street, Inc. 1-800-4-WALL-ST
WallStreet Direct, Inc.
CONTACT: Nick Iyer of Digital Wall Street, Inc., 1-800-4-WALL-ST
